Drug intelligence / Profile preview

Bria-OVA+

Development stage: Preclinical
Lead developer: BriaCell Therapeutics
Modality: Cell Therapies
Administration: Intradermal

Overview

Bria-OVA+ is a next-generation, personalized, off-the-shelf, cell-based immunotherapy candidate developed by BriaCell Therapeutics for the treatment of ovarian cancer. Built on the Bria-OTS+ platform, it is designed to engage and activate the immune system against tumor cells through multiple mechanisms, including CD40 ligand (CD40L) stimulation, CD80 stimulation, and CD86 inhibition. As a cellular biologic, it incorporates immune-stimulating components to enhance anti-tumor activity and provide a targeted approach to ovarian cancer treatment.

Brand names: Bria-OVA+

Beyond the preview

Go deeper on Bria-OVA+.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bria-OVA+.

Explore the full profile